China Meheco Group's (SHA:600056) unit, China National Pharmaceutical and Healthcare Industry, received the Chinese drug administration's approval on its supplementary application for tranexamic acid injection after the drug passed the regulator's consistency evaluation, according to a Shanghai Stock Exchange disclosure on Tuesday.
The evaluation tested the efficacy and quality of the drug, which is mainly used for acute or chronic, localized or systemic primary fibrosis, the pharmaceutical company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments